Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

At the end of the treatment evaluation, they also looked at progression ... Depth of remission is key in myeloma because it ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Newer treatments, including anti-CD38 monoclonal antibodies and immunomodulating agents, are becoming standard in multiple myeloma management. In patients with relapsed or refractory multiple myeloma, ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...

Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a ...

Thanks to Joanna from Poland, I have no measurable leukemia. Getting college-age kids to join the bone-marrow donor registry ...

Affecting approximately 4,500 people annually in the U.S., AL amyloidosis can be associated with blood cancers, particularly multiple myeloma as well as lymphomas or chronic lymphocytic leukemia.